MarketPeel
Insider Trading Intelligence
Pricing
…
ED

Edward J. III Dulac

FATE
CHIEF FINANCIAL OFFICER · FATE THERAPEUTICS INC · CIK 0001821530
FILING MIX · LIFETIME46%/54%
BUYS
17
SELLS
20
TOTAL VALUE
$4.15M
COMPANIES
2
ACTIVE SINCE
Aug 2020
HOLDINGS NOW
189,022
AVG SELL PX
$33.62
TRADE KIND
SHOWING 37 / 37
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Edward J. III Dulac, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+50.00%-0.85%+0.26%-1.11%-1.77%—
14d18+61.11%-0.38%-0.34%-0.04%-3.41%—
30d18+66.67%+1.64%+0.03%+1.61%-9.10%—
60d18+66.67%+4.34%-0.58%+4.93%-17.67%—
90d18+72.22%+2.16%+2.76%-0.61%-18.57%—
180d18+83.33%-21.37%+3.77%-25.14%-35.53%—
1y18(2 pending)+93.75%-63.31%+7.15%-70.45%-71.55%—
2y18(2 pending)+100.00%-83.83%+25.99%-109.82%-109.43%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
FATE · 101,479 shares · as of Mar 4, 2024
0106,250212,500318,750425,0002021202220232024SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 17 buys / 20 sellsCOVERAGE · 23 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
61,280——160,963Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
87,543——87,543Mar 1, 2026Mar 3, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Financial Officer
6,379$9.21$58.8K99,683Jan 5, 2026Jan 7, 2026 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
EVP, Chief Financial Officer
7,462$14.02$104.6K106,062Jul 23, 2025Jul 25, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
47,200——113,524Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
67,429——67,429Mar 1, 2025Mar 4, 2025 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
96,219——96,219Jul 22, 2024Jul 24, 2024 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
66,324——66,324Jul 22, 2024Jul 24, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
2,447$7.77$19.0K101,479Mar 4, 2024Mar 5, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
425,000——425,000Feb 1, 2024Feb 2, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
1,849$5.00$9.2K103,926Jan 29, 2024Jan 30, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
7,028$4.37$30.7K105,775Jan 9, 2024Jan 10, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
5,182$3.66$19.0K112,803Jan 2, 2024Jan 3, 2024 ↗View →
FATE
FATE THERAPEUTICS INC
SALE10b5-1
10b5-1 plan
1,585$3.50$5.5K117,985Dec 18, 2023Dec 19, 2023 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
4,718$2.80$13.2K119,570Aug 18, 2023Aug 21, 2023 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
425,000——425,000Feb 6, 2023Feb 7, 2023 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
7,331$5.24$38.4K129,470Jan 10, 2023Jan 11, 2023 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
432$30.41$13.1K136,801Aug 18, 2022Aug 19, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
4,703$29.75$139.9K137,233Aug 18, 2022Aug 19, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
53,058——53,058Jan 25, 2022Jan 27, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
33,302——141,936Jan 25, 2022Jan 27, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
1,380$48.25$66.6K109,024Jan 11, 2022Jan 13, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
390$49.16$19.2K108,634Jan 11, 2022Jan 13, 2022 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
15,977$60.00$958.6K110,404Dec 20, 2021Dec 21, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Financial Officer
14,437$35.52$512.8K126,381Dec 20, 2021Dec 21, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
14,437——128,238Dec 20, 2021Dec 21, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
59,540——111,944Nov 19, 2021Nov 22, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASE
Chief Financial Officer
17,325$35.52$615.4K71,864Sep 28, 2021Sep 30, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
19,460$62.53$1.22M52,404Sep 28, 2021Sep 30, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
17,325——142,675Sep 28, 2021Sep 30, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
1,937$87.90$170.3K56,076Aug 19, 2021Aug 20, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
1,474$88.65$130.7K54,602Aug 19, 2021Aug 20, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
SALE
Chief Financial Officer
63$90.00$5.7K54,539Aug 19, 2021Aug 20, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
6,851——6,851Jan 20, 2021Jan 22, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
18,013——58,013Jan 20, 2021Jan 22, 2021 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
160,000——160,000Aug 17, 2020Aug 19, 2020 ↗View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
40,000——40,000Aug 17, 2020Aug 19, 2020 ↗View →
Other insiders · FATE
Loading peer insiders…
About this filer
CIK 0001821530
ROLE
Chief Financial Officer
PRIMARY
FATE
COMPANIES
2
ACTIVE SINCE
Aug 2020
MARKETPEEL · /INSIDER/0001821530DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback